You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
南新制藥(688189.SH)控股子公司獲臨牀試驗通知書
格隆匯 06-01 18:23

格隆匯6月1日丨南新制藥(688189.SH)公佈,公司控股子公司廣州南鑫藥業有限公司於近日收到國家藥監局核准簽發的帕拉米韋吸入溶液《臨牀試驗通知書》。

帕拉米韋氯化鈉注射液是公司開發上市的治療流感一線用藥,驗證了帕拉米韋治療流感的安全性和療效。帕拉米韋吸入溶液為公司自主研發的國家2類新藥,是對公司現有1.1類新藥帕拉米韋氯化鈉注射液的劑型創新。

吸入溶液霧化吸入療法是利用氣動式霧化器或超聲霧化器的空化作用,使液體在氣相中分散,將藥液變成霧狀顆粒,通過正常呼吸,直接吸入霧狀藥物顆粒作用於呼吸道病灶局部的治療方法。

公司控股子公司廣州南鑫藥業有限公司將於近期開展帕拉米韋吸入溶液用於甲型或乙型流行性感冒的臨牀試驗。考慮到藥品研發過程中不可預測因素較多,敬請廣大投資者謹慎決策,注意防範投資風險。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account